benzoxazoles has been researched along with Squamous Cell Carcinoma of Head and Neck in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, B; Huang, L; Li, H; Liang, Y; Liao, G; Luo, H; Shi, S; Wang, L; Wang, Z; Xia, J; Xu, B | 1 |
| Cheng, B; Deng, M; Fan, Z; Liang, X; Ping, F; Ren, X; Tao, X; Wang, H; Wang, Y; Wu, T; Xia, J; Xu, J; Zhang, C | 1 |
2 other study(ies) available for benzoxazoles and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzothiazoles; Benzoxazoles; Cell Line, Tumor; Cell Proliferation; DNA End-Joining Repair; DNA, Ribosomal; Drug Synergism; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Naphthyridines; Protein Kinase Inhibitors; Pyrimidines; Reactive Oxygen Species; RNA Polymerase I; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2021 |
Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoxazoles; Carcinogenesis; Drug Synergism; Female; Histone Deacetylase 1; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred BALB C; Mouth Neoplasms; Neoplasm Recurrence, Local; Pyrimidines; Random Allocation; Rats; SOXB1 Transcription Factors; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2019 |